Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,836 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06832202RecruitingPhase 2
HLX22 plus Enhertu for HR+, HER2-low breast cancer
This trial tests a new drug, HLX22, combined with Enhertu (trastuzumab deruxtecan) for people with advanced breast cancer that is hormone receptor positive and HER2-low. The goal is to see if the combination works better than Enhertu alone.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06937177RecruitingPhase 2
Testing mifomelatide to help maintain weight during chemo
This trial tests an investigational drug called mifomelatide (TCMCB07) to see if it can help people with newly diagnosed colorectal or pancreatic cancer maintain a healthy weight while receiving certain types of chemotherapy. You would give yourself a daily injection under the skin.
Tucson, ArizonaAges 18 years+ - NCT06940739RecruitingPhase 1/Phase 2
IOV-3001 and lifileucel for advanced melanoma
This trial tests a new combination treatment, IOV-3001 and lifileucel, for people with advanced melanoma that has not responded to standard immunotherapy and cannot be surgically removed. It aims to see if this cellular therapy is safe and effective.
Denver, ColoradoAges 18–70 - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Hot Springs, ArkansasAges 18 years+ - NCT06927986RecruitingPhase 3
Testing SYS6010 vs chemo for advanced EGFR-mutated lung cancer
This trial tests a new drug called SYS6010 compared to standard chemotherapy for people with EGFR-mutated lung cancer that has stopped responding to pill treatments. It may offer a new option if your current EGFR TKI is no longer working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06276283RecruitingPhase 2
DZD9008 plus bevacizumab for EGFR-mutated advanced lung cancer
This trial tests a new targeted therapy (DZD9008) combined with a drug that blocks blood vessel growth (bevacizumab) for people with a specific type of advanced lung cancer (EGFR mutation). The goal is to see if this combination works better than current treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05451043RecruitingPhase 2
Durvalumab and tremelimumab plus chemotherapy with propranolol
This Phase 2 study tests whether adding propranolol to durvalumab and tremelimumab along with chemotherapy can help control advanced pancreatic cancer, liver cancer, or bile duct cancer. It aims to shrink tumors and help people live longer or feel better when the cancer can’t be cured with surgery or local treatment.
Edmonton, AlbertaAges 18 years+ - NCT06890871Enrolling by invitationPhase 1/Phase 2
Radiation with immunotherapy and anti-angiogenic therapy for advanced HER2-negative breast cancer
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
Wuhan, HubeiAges 18–75 - NCT06887348Recruiting
Long-term safety study for prior RP1, RP2, or RP3 patients
This study checks the long-term safety of patients who have already received RP1, RP2, or RP3 treatment in a previous study. It helps doctors understand any side effects that may appear over time.
La Jolla, CaliforniaAges 18 years+ - NCT06883136Enrolling by invitation
Sintilimab plus chemo for elderly advanced lung cancer
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
Jinan, ShandongAges 60–80 - NCT06669117RecruitingPhase 1/Phase 2
VERT-002 for solid tumors with MET changes
This trial tests a new drug, VERT-002, for people with advanced solid tumors, including non-small cell lung cancer (NSCLC), that have specific changes in the MET gene. It aims to see if the drug can shrink tumors or stop them from growing when other treatments haven't worked or aren't available.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06863311RecruitingPhase 2
Trial of zanzalintinib with immunotherapy for advanced kidney cancer
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06861543RecruitingPhase 1
TMT101 for advanced pancreatic or lung cancer
This trial tests a new drug called TMT101 for people with advanced pancreatic cancer or non-small cell lung cancer who have already tried other treatments. The goal is to see if TMT101 is safe and works against the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06859684RecruitingPhase 2
Triple therapy for advanced bile duct cancer of the liver
This trial tests a combination of three treatments for people with advanced bile duct cancer that cannot be removed by surgery or has spread. The treatments include a chemotherapy infusion directly into the liver artery (HAIC), an immunotherapy drug (durvalumab), and a targeted therapy pill (lenvatinib). It aims to see if this triple therapy can shrink or control the cancer better than standard treatments.
Chengdu, SichuanAges 18–75 - NCT06855771RecruitingPhase 2
Study of navlimetostat alone or with izalontamab for advanced lung cancer
This trial tests a new drug, navlimetostat, either by itself or combined with another drug, izalontamab, for people with advanced non-small cell lung cancer that has a specific genetic change (MTAP loss). The goal is to see if these treatments can help shrink tumors or slow cancer growth.
Anchorage, AlaskaAges 18 years+ - NCT06856187RecruitingPhase 2
Second-line chemo plus TAS-102 combo for advanced colorectal cancer
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
Shanghai, Shanghai MunicipalityAges Any age - NCT06838273RecruitingPhase 3
Testing a new drug combo for EGFR-mutated lung cancer
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06844383RecruitingPhase 2
Talazoparib with or without enzalutamide for prostate cancer after prior treatment
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT06826313RecruitingPhase 1
Virus treatment for advanced solid tumors
This trial tests an intravenous virus treatment (VRT106) for people with advanced solid tumors that have stopped responding to standard therapies. The goal is to see if the virus can target and help control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06828588RecruitingEarly Phase 1
A new imaging test for people on HER2 cancer therapy
This study tests a new imaging drug called [68Ga]Ga-ABY-025 to see how well it shows HER2-positive tumors in people who are about to start or have just started HER2-targeted cancer therapy. It may help doctors see if the treatment is working.
Nashville, TennesseeAges 18 years+ - NCT06835387RecruitingPhase 2
Combination Chemotherapy for Advanced Small Bowel Cancer
This trial tests a combination of chemotherapy drugs (NALIRIFOX) for people with advanced small bowel adenocarcinoma that cannot be surgically removed. It is for those who have not yet had treatment for their advanced cancer, except possibly one cycle of FOLFOX.
Tampa, FloridaAges 18 years+ - NCT06834204Enrolling by invitation
Better care coordination for cancer survivors
This study tests a program to improve communication between your cancer team and your regular doctor. If you have heart or diabetes risks and you're being treated for breast, prostate, bladder, or endometrial cancer, this trial may help coordinate your care.
New Brunswick, New JerseyAges 18 years+ - NCT06833229Recruiting
Can a PET scan predict if immunotherapy is working?
This study uses a special PET-CT scan early in your treatment to see if immunotherapy (with or without chemotherapy) is working against your advanced lung cancer. The goal is to find out faster if the treatment is helping.
NiceAges 18 years+ - NCT06805825RecruitingPhase 1
Study of NN3201 for advanced cancers with c-Kit
This trial tests a new drug, NN3201, that targets a protein called c-Kit found on some cancer cells. It may be an option for people with certain advanced solid tumors, including GIST, small cell lung cancer, or other c-Kit-positive cancers, who have already tried standard treatments or cannot take them.
Ann Arbor, MichiganAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,836 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.